Clinical trial
A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic…
NCT03219554 · Samsung Medical Center, Other · Unknown status
Key facts
| NCT number | NCT03219554 |
|---|---|
| Title | A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor |
| Official title | Samsung Medical Center |
| Lead sponsor | Samsung Medical Center, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thymic Cancer |
| Intervention type | Drug |
| Interventions | Palbociclib |
| Enrollment | 33 |
| Start date | Aug 1, 2017 |
| Primary completion | Dec 1, 2019 |
| Completion | Dec 1, 2020 |
| First posted | Jul 17, 2017 |
| Last update posted | Aug 2, 2017 |
| Countries | South Korea |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: